Xeltis announces multidisciplinary Scientific Advisory Board of global leading experts
01 . 11 . 2016

Xeltis announces multidisciplinary Scientific Advisory Board of global leading experts

Xeltis has established its Scientific Advisory Board, uniting world-class experts across different disciplines: from supramolecular chemistry, to experimental surgery and medical technology. The Scientific Advisory Board will support Xeltis’ robust development program, based on the most advanced scientific foundations in each field. The board includes nine members:

– Michael Colson, Chairman: Medical device development consultant, former R&D Executive at Medtronic
– Richard Bianco: Director Experimental Surgery at University of Minnesota
– Geoffrey Gurtner: Professor of Plastic & Reconstructive Surgery and Professor of Bioengineering at Stanford University School of Medicine
– Jeffrey Hubbell: Professor of Molecular Engineering Innovation and Enterprise at University of Chicago
– Jean-Marie Lehn: Nobel Laureate and Director of the Supramolecular Chemistry Laboratory at the Institute of Supramolecular Science and Engineering in Strasburg
– Nicolas L’Heureux: Director of Research at INSERM Unité 1026 BioTis, Université de Bordeaux
– Bert Meijer: Professor and Head of the Institute for Complex Molecular Systems at Eindhoven University of Technology
– Jim Oberhauser: Associate Director, Device Development and Clinical Packaging Engineering at Gilead, Medical Device Consultant
– Fred Schoen: Professor of Pathology at Brigham Hospital and Harvard Medical School, Boston

The Scientific Advisory Board will complement the ongoing work of Xeltis’ Clinical Advisory Board, which comprises seven cardiovascular experts. The two advisory boards combined will help Xeltis to identify and meet fundamental cardiovascular needs with the most advanced technology and devices.

“Xeltis has attracted global leading experts in a number of key disciplines, which, for a relatively small and young company, is truly remarkable. It demonstrates the pace at which Xeltis is working, as well as the potential for ETR in cardiovascular treatment,” commented Xeltis CEO Laurent Grandidier.

For SAB members’ biographies, please click here.

Learn more about ETR.

Go back